Recall of ARCHITECT Active-B12 (Holotranscobalamin). An in vitro diagnostic medical device (IVD)

According to Department of Health, Therapeutic Goods Administration, this recall involved a device in Australia that was produced by Abbott Australasia Pty Ltd Diagnostic Division.

What is this?

A correction or removal action taken by a manufacturer to address a problem with a medical device. Recalls occur when a medical device is defective, when it could be a risk to health, or when it is both defective and a risk to health.

Learn more about the data here
  • Type of Event
  • Event ID
  • Event Risk Class
    Class II
  • Event Initiated Date
  • Event Country
  • Event Source
  • Event Source URL
  • Notes / Alerts
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Extra notes in the data
  • Reason
    Abbott has confirmed that the architect active-b12 assay is not meeting the method comparison slope claim of 1.0 +/- 0.1 as stated in the package insert (commodity number abbl331/r02). a positive bias of approximately 20-30% has been observed when compared to a commercially available diagnostic kit.This recall action was not notified to the tga before it was initiated by abbott.
  • Action
    Abbott is providing work around instructions for users to follow and is advising users that once they receive the next reagent lot after the affected lots to re-establish the laboratory's reference ranges prior to evaluating future patient results.


  • Model / Serial
    ARCHITECT Active-B12 (Holotranscobalamin). An in vitro diagnostic medical device (IVD)List Numbers: 3P24-25 / 3P24-35Lot Numbers: 10112UP00, 10113UP00 and 1013UP00
  • Manufacturer


  • Manufacturer Parent Company (2017)
  • Manufacturer comment
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source